Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease

Plugin JSON Content Importer Pro not running: Check Licence! Check that a Licence is active for https://freeline.life
You might also like
Freeline Announces $26.1 Million Registered Direct Offering of American Depositary Shares
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freeline to participate at Conferences during January 2021
Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Get in touch

+44 (0)1438 906870
contact@freeline.life

Follow us on our social channels